Journal of Allergy and Clinical Immunology
Chapter 29Transplantation immunology: Solid organ and bone marrow
Section snippets
MHC
Histocompatibility antigens are tissue cell-surface antigens capable of inducing an immune response in a genetically dissimilar (allogeneic) recipient, resulting in the rejection of the tissues or cells bearing those antigens. The genes that encode these antigens reside in the MHC region on the short arm of human chromosome 6 (Fig 1). The HLA complex contains more than 200 genes, more than 40 of which encode leukocyte antigens.2, 3 These genes and their encoded cell-surface and soluble protein
Role of alloimmune antibodies
The strongest evidence for a role for antibodies in graft rejection is the hyperacute rejection of primarily vascularized organs, such as the kidney and heart. High titers of antidonor antibodies can be demonstrated in recipients presenting with these reactions.6 These antibodies combine with HLA antigens on endothelial cells, with subsequent complement fixation and accumulation of polymorphonuclear cells. Endothelial damage then occurs, probably as a result of enzymes released from
Immunosuppression
More information on immunosuppresion regimens can be found in Table I.
Currently, there is no method that will suppress the host's immune response to antigens of the graft and at the same time maintain other immune responses. Nonspecific immunosuppressive agents are needed to prevent rejection of the transplanted organ, which can occur even though HLA-matched donors are used. The development of immunosuppressive strategies during the past 4 decades reflects enormous progress in understanding the
Solid-organ transplantation
The explosive growth of transplantation since the discovery of HLA in 1967 is attested to by the fact that, according to the Global Database on Donation and Transplantation gathering data from 97 countries, in 2007 around 100,000 solid-organ transplantations were performed per year worldwide: 68,250 are kidney transplantations (45% from living donors), 19,850 are liver transplantations (14% from living donors), 5,179 are heart transplantations, 3,245 are lung transplantations, and 2,797 are
Bone marrow transplantation
Since 1955, more than 240,000 bone marrow transplantations have been performed worldwide at 450 centers in 47 countries for the treatment of more than 50 different fatal diseases (Table III).42 Most of these transplantations have been done by reinfusing stored autologous marrow cells collected before the patient receives intensive chemotherapy or irradiation. Annually, 25,000 to 35,000 autologous transplantations are performed compared with approximately 15,000 allogeneic transplantations.
Conclusions
Advances in transplantation immunology have allowed the exponential growth of organ and tissue transplantation in medicine over the last 3 decades. Newer immunosuppressive agents have allowed the control of solid-organ and tissue rejection and GVHD, even when HLA incompatibility is present. For the treatment of hematologic disorders, including primary immunodeficiencies, hematopoietic stem cell transplantation is not only feasible but is also the treatment of choice in many cases. Future
References (107)
- et al.
Hyperacute rejection of kidney allografts associated with pre-existing humoral antibodies against donor cells
Lancet
(1966) - et al.
The role of ABO-incompatible living donors in kidney transplantation: state of the art
Semin Nephrol
(2007) - et al.
Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry
Biol Blood Marrow Transplant
(2008) Cyclosporine: a revolution in transplantation
Transplant Proc
(1999)- et al.
Role of TH1/TH2 cytokines in kidney allograft rejection
Transplant Proc
(2008) Forty years of publication of transplantation proceedings—the second decade: the cyclosporine revolution
Transplant Proc
(2009)- et al.
Heart and lung transplantation in children
Lancet
(2006) - et al.
Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4 + CD25+ regulatory T cells
Blood
(2006) - et al.
Global observatory and database on donation and transplantation: world overview on transplantation activities
Transplant Proc
(2009) - et al.
Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection
Am J Transplant
(2009)
A novel approach to successful ABO-incompatible high-titer renal transplantation
Transplant Proc
Long term outcomes for whole and segmental liver grafts in adult and pediatric liver transplant recipients: a 10- year comparative analysis of 2,988 cases
J Am Coll Surg
Registry of the International Society for Heart and Lung Transplantation: eleventh official pediatric lung and heart/lung transplantation report—2008
J Heart Lung Transplant
Registry of the International Society for Heart and Lung Transplantation: a quarter century of thoracic transplantation
J Heart Lung Transplant
Human marrow transplantation: an immunological perspective
Adv Immunol
The clinical spectrum of acute graft-versus-host disease
Semin Hematol
Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study
Biol Blood Marrow Transplant
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
Lancet Oncol
Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation
Biol Blood Marrow Transplant
Graft-vs-host disease
Lancet
Severe combined immunodeficiency with natural killer cell predominance: abrogation of graft-versus-host disease and immunologic reconstitution with HLA-identical bone marrow cells
J Allergy Clin Immunol
Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras
Blood
Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99
Lancet
Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency
J Allergy Clin Immunol
Long-term outcome after haematopoietic stem cell transplantation of a single-centre cohort of 90 patients with severe combined immunodeficiency: long-term outcome of HSCT in SCID
Blood
In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDX1)
Lancet
Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation
Blood
Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program
Blood
Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome
J Pediatr
Bone marrow transplantation in major histocompatibility complex class II deficiency: a single center study of 19 patients
Blood
Immunologic reconstitution following bone marrow transplantation for X-linked hyper IgM syndrome
Clin Immunol
Correction of purine nucleoside phosphorylase deficiency by transplantation of allogeneic bone marrow from a sibling
J Pediatr
Treatment of infants with complete DiGeorge anomaly
J Allergy Clin Immunol
Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants
Blood
Hematopoietic stem cells transplantation for malignant diseases
Acute myelogenous leukemia
Exp Hematol
The cure of thalassemia by bone marrow transplantation
Blood Rev
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia
Biol Blood Marrow Transplant
Bone marrow transplantation for autosomal recessive osteopetrosis
J Pediatr
Hematopoietic cell therapy for metabolic disease
J Pediatr
Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives
Biol Blood Marrow Transplant
Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector
Lancet
Hu-1: major histocompatibility locus in man
Science
The HLA dictionary 2008: a summary of HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens
Tissue Antigens
The HLA system: first of two parts
N Engl J Med
WHO Nomenclature Committee for Factors of the HLA System. Nomenclature for factors of the HLA system, update
Tissue Antigens
The HLA system: second of two parts
N Engl J Med
The role of major histocompatibility complex class I chain-related gene A antibodies in organ transplantation
Curr Opin Organ Transplant
Correlation of the relative response index with marrow graft rejection in patients with aplastic anemia
Transplantation
Hematopoietic stem cell transplantation for the treatment of severe combined immunodeficiency
N Engl J Med
Cited by (128)
Cardiac Regeneration Using Pluripotent Stem Cells and Controlling Immune Responses
2023, Heart Lung and CirculationTransplantation
2022, Clinical ImmunologyChondro-inductive hyaluronic acid/chitosan coacervate-based scaffolds for cartilage tissue engineering
2021, International Journal of Biological MacromoleculesThe immunology of solid organ transplantation
2021, Anaesthesia and Intensive Care Medicine
Disclosure of potential conflict of interest: J. Chinen has declared that he has no conflict of interest. R. H. Buckley has received research support from the National Institute of Allergy and Infectious Diseases and is the Chair of the Medical Advisory Committee for the Immune Deficiency Foundation.